

()

(H. pylori, C. pneumonia, Hrepes Simplex Virus, Cytomegalovirus)

*

**

HDL

CMV HSV-1

(/)

ATPIII NCEP

P= /) (OR= / P= /) (OR= / P = /) HSV

(OR= / P= /) (OR= / P= /) (OR= /

(OR= / P= /) CMV

HSV-1 CMV

// : - // : - // :

*

**

.()

X :
.()

(WHO)

NCEP ATP III

NCEP ATP III

.()

)

HDL

(/
.()

ATP III WHO
.()

NCEP

I

II

.()

(

I

)

.(

()

/

/

CMV HSV-1

Selectra 2 autoanalyzer »
« (Vital specific,The Netherlands)

I

=<

colorimetric method enzymatic)
(glucose oxidase
(Pars Azmun Inc;Tehran, Iran)

HDL

(oxidase phenol aminoantipyrine cholesterol)

enzymatic – method glycerol -3 phosphate)
(oxidase phenol aminoantipyrine
LDL

: (

(Friedman Formula)

: (

National cholesterol Education)

(Program’s Adult Treatment panel III =ATP III

«WHO MONICA»

:HDL

« Standimeter »

BMI .(

ECG .

.()

() ATP(III)
 ECG
 /)
 (/) (IHD
 /
 (P= /) / ECG
 ()
 (P= /)
 IgG
 CMV (EIA)
 (P< /) DRG
 EIU
 CMV (P> /) CMV EIA IgG
 RADIM
 UR/ml
 HSV-1 EIA CMV IgG
 RADIM
 HSV-1 (P= /) IgG RU/ml
 EIA HSV-1
 (P= /) RADIM
 ()
 (P= /) * Chi-square
 «Two-Tailed test»
 (P= /) P > /
 (P= /)
 (P= /)
 IHD-ECG
 ()
 IBM
 (P= /) SPSS 9.05 (SPSS Inc;Chicago,IL)

/

/

(

P	CI	OR	P	CI	OR	
/	/ /	/ % / % /	N.S	/ /	/ % / % /	HSV-1
N.S	/ /	/ % / % /	/	/ /	/ % / % /	CMV
/	/ /	/ % / % /	/	/ /	/ % / % /	
/	/ /	/ % / % /	/	/ /	/ % / % /	

.(P= /)

.(P= /)

CMV

.(P= /)

LDC

(P> /)

(injury)

CMV

.(P= /)

HSV-1

(P= /)

(foam cell)

HSV-1

(fatty streaks)

.(P> /)

T

(mast cell)

HSV-1

CMV

.()

(National Health And Nutrition

NHANES Examination Survey)(III)

()

()

()

CRP

hs-CRP(High Sensitive-CRP)

CRP

()

IL-6 TNF- α

CRP

()

()

CRP

()

:

Proinflammatory

TNF- α (Tumor Necrosis Factor- α) CRP

A

IL6(Interleukin-6)

(Adiponectin)

Leptin

HSV1 CMV

)

CRP

(IL6

()

()

HDL-C

HSP-60

(anti HSP-60)

CRP

IL6

(hypercoagulation)

CRP IL6

CRP (adhesion)

IL6 .

.()

IL6

.()

.()

IL6 TNF- α IL6 TNF- α

6

TNF- α TNF- α

(Serine)

(IRS-1)

(IRS-1)

.()

.()

References:

1. Ferrannini E, Haffner SM, Mitchell BD, et al. Hyperinsulinemia. the key feature of a cardiovascular and metabolic syndrome. *Diabetologia* 1991;34:416-22.
2. Expert Panel on Detection ,Evaluation and Treatment of High Blood Cholesterol in Adults :Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection ,Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
3. Bonora E, Kiechl S,Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. *Diabetes Care* 2003; 26:1251-7.
4. McNeill AM, Rosamond WD, Cynthia J, et al.The Metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. *Diabetes Care* 2005;28:385-90.
5. Fabricant CG, Fabricant J. Minick CR, et al. Herpesvirus-induced atherosclerosis in chickens. *Fed Proc* 1983;42:2476-9.
6. Shih SCH, Pullman EP, Jao KJ. Genetic selection, general characterization, and history of atherosclerosis-susceptible and resistance Japanese quail. *Atherosclerosis* 1983;49:41-53.
7. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. *JAMA* 1990;263:2204-07.
8. Adam E, Melnick JL, Probstfield JL, et al. High levels of cytomegalovirus antibody in patients

requiring vascular surgery for atherosclerosis. *Lancet* 1987;2:291-3.

9. Melnick JL, Adam E, DeBakay ME. Cytomegalovirus and atherosclerosis. *Eur Heart J* 1993; 14(suppl 1):30-8.

10. Yamashiroya HM, Ghoch L, Yang R, et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. *Am J Pathol* 1988;130:71-9.

11. Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus /herpesvirus and carotid atherosclerosis: the ARIC Study. *J Med Virol* 1993;42:33-7.

12. Saikku P, Mattila K, Nieminen MS, et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. *Lancet* 1988;2:983-6.

13. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. *Ann Intern Med* 1992;116:273-8.

14. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. *JAMA* 1992;268:68-72.

15. Kuo CC, Grayston JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). *Proc Natl Acad Sci USA* 1995;92:6911-14.

16. Havlik RJ, Blackwelder WC, Kaslow R, et al. Unlikely association between clinically apparent herpesvirus infection and coronary incidence at older ages: the Framingham Heart Study. *Arteriosclerosis* 1989;9:877-80.

17. Grayston GT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. *Circulation* 1995;92:3397-400.

18. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary artery disease. *Br Heart J* 1994;71:437-9.

19. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. *Circulation* 2004; 109:II-2-II-10.

20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002;287:356-9.

21. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8 year follow up of 14719 initially healthy American women. *Circulation* 2003; 107:391-7.

22. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? *Eur Heart J* 2002;23:831-4.

23. Sridevi D, Rosenson RS, Ishwarlal J, et al. Metabolic syndrome: an appraisal of the pro-inflammatory and pro-coagulant status. *Endocrinol Metab Clin N Am Part 1* 2004;33:431-53.

24. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. *Circulation* 1996;93:1809-17.

25. Fernandez-Real JM, Wifredo R. Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocrine Rev* 2003;24:278-301.

26. Espinola-Klein C, Ruppricht SJ, Blankenberg S, et al. Are morphological or functional changes in the carotid artery wall associated with C. pneumoniae, H. pylori, CMV or HSV infections? *Stroke* 2000;31:2127-33.

27. Aristo V. A look at infectious agents as a possible causative factor in cardiovascular disease. *Science* 2003;34:6-11.

28. Vercellotti GM. Microbes, inflammation and atherosclerosis: will old pathology lessons guide new therapies? *Trance Am Clin Climatol Assoc* 2001;112:215-22.

29. Engelman JA, Berg AH, Renee Y, et al. Tumor necrosis factor- α mediated insulin resistance, but not de differentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. *Molecular Endocrinol* 2000;14: 1557-69.

30. Hotamisligil GS, Murray DL, Choy LN, et al. Tumor necrosis factor- α inhibits signaling from the insulin receptor. *Biochemistry* 1994;91:4854-8.